Advances in stem cell transplantation strategies show promise to improve availability, success
Hematopoietic stem cell transplantation (HSCT), once considered an effective yet risky alternative to drug therapy for blood cancer, has become more accessible and successful in a wide range of patients as a result of major advances in transplant strategies and technologies. Several studies representing these advances were presented during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans. Researchers from the Johns Hopkins Kimmel Cancer Center presented a study of haploidentical bone marrow or peripheral blood stem cell transplants (haploBMT) as an alternative to fully matched transplants. Researchers from the City of Hope Cancer Center presented a study exploring whether transplants – and specifically the intensity of transplant-related chemotherapy and radiation – might be associated with cognitive decline.
Click here to read the full press release.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.